Check for updates

OPEN ACCESS

EDITED BY Juei-Tang Cheng, Chang Jung Christian University, Taiwan

REVIEWED BY Dongwei Zhang, Beijing University of Chinese Medicine, China Tosin Abiola Olasehinde, University of Fort Hare, South Africa

*CORRESPONDENCE Bodong Lv, lbd168@ziu.edu.cn

SPECIALTY SECTION This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology

RECEIVED 30 May 2022 ACCEPTED 29 August 2022 PUBLISHED 21 September 2022

CITATION

Feng Y, Shi T, Fu Y and Lv B (2022), Traditional chinese medicine to prevent and treat diabetic erectile dysfunction. *Front. Pharmacol.* 13:956173. doi: 10.3389/fphar.2022.956173

COPYRIGHT

© 2022 Feng, Shi, Fu and Lv. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Traditional chinese medicine to prevent and treat diabetic erectile dysfunction

Yanfei Feng¹, Tianhao Shi¹, Yuli Fu¹ and Bodong Lv^{2,3}*

¹The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China, ²Zhejiang Province Key Laboratory of Traditional Chinese Medicine (Laboratory of Andrology), Hangzhou, China, ³Department of Urology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

Diabetic erectile dysfunction (DED) is one of the most common complications of diabetes mellitus. However, current therapeutics have no satisfactory effect on DED. In recent years, traditional Chinese medicine (TCM) has shown good effects against DED. By now, several clinical trials have been conducted to study the effect of TCM in treating DED; yet, the underlying mechanism is not fully investigated. Therefore, in this review, we briefly summarized the pathophysiological mechanism of DED and reviewed the published clinical trials on the treatment of DED by TCM. Then, the therapeutic potential of TCM and the underlying mechanisms whereby TCM exerts protective effects were summarized. We concluded that TCM is more effective than chemical drugs in treating DED by targeting multiple signaling pathways, including those involved in oxidation, apoptosis, atherosclerosis, and endothelial function. However, the major limitation in the application of TCM against DED is the lack of a largescale, multicenter, randomized, and controlled clinical trial on the therapeutic effect, and the underlying pharmaceutical mechanisms also need further investigation. Despite these limitations, clinical trials and further experimental studies will enhance our understanding of the mechanisms modulated by TCM and promote the widespread application of TCM to treat DED.

KEYWORDS

diabetic erectile dysfunction, traditional Chinese medicine, Chinese herbs, endothelial dysfunction, vasculopathy, oxidative stress

Introduction

Erectile dysfunction (ED) is one of the secondary complications of diabetes mellitus (DM) and affects >37% of men with DM (Maiorino et al., 2017), more than three times of the prevalence in men without DM (Malavige and Levy, 2009). According to a recent study, the estimated prevalence of DM is approximately 12.4% in China (Wang L. et al., 2021). Furthermore, the prevalence of DM between 2021 and 2045 is estimated to be 21.1% in middle-income countries, including China (Sun et al., 2022). Therefore, a large number of men in China will presumably suffer from the high medical costs and poor life quality associated with diabetic ED (DED). Although the association between DM and the development of ED has been documented since 1970s, the mechanism underlying DED

has not been fully characterized yet (Gur et al., 2014). Increasing attention has been given to ED in men with DM due to the multifactorial pathophysiology involved, including neuropathy, macrovascular arterial disease, structural remodeling of the corporeal tissue, and hormonal imbalance (Kamenov, 2015).

Currently, the most commonly used method in the treatment of ED is chemical drugs therapy; however, this treatment has limitations in treating DED (Kamenov, 2015). Phosphodiesterase type 5 (PDE5) inhibitors currently represent the first-choice treatment strategy for ED. However, the beneficial effect of this treatment is lower in diabetic than in non-diabetic subjects (Bruzziches et al., 2008). It has been reported that sildenafil, a commonly used inhibitor of PDE5, can improve the sexual function in approximately 63% of DM patients, whereas beneficial effects have been observed in approximately 83% of non-diabetic subjects (Fink et al., 2002). The reduced responsiveness to PDE5 inhibitors in men with DM may be related to the severity of neuropathy (Musicki and Burnett, 2007). Additionally, PDE5 inhibitors can induce adverse effects, such as facial redness, headache, or gastrointestinal reactions (Condorelli et al., 2013; Vita et al., 2019). Therefore, a novel therapeutic approach is urgently needed.

In recent years, traditional Chinese medicine (TCM) has shown good effects against DED (Yin and Fang, 2019). According to a previous study, combined use of PDE5 inhibitors with TCM can promote the blood circulation, and the clinical efficacy obtained is often higher than that seen with the use of PDE5 inhibitors alone (Luo et al., 2019). Therefore, an in-depth understanding of the molecular mechanisms underlying DED is required to establish new treatment methods and targets that can improve the life quality of DM patients.

We searched the electronic databases of PubMed, Embase, the Cochrane Library and China National Knowledge Infrastructure (CNKI) via the following terms: 1) "Traditional Chinese medicine" or "Chinese medicine" or "herb" or "Chinese herb" and 2) "diabetic erectile dysfunction" or "diabetes erectile dysfunction" or "erectile dysfunction". The search was limited to the studies published in English or Chinese. The final literature search was performed on May 5, 2022.

In this review, we summarize the current understanding of the molecular mechanisms underlying DED, including the risk factors and pathogenesis and discussed the therapeutic effect of TCM on DED.

Risk of DED

Numerous risk factors, including aging, duration of DM, poor glycemic uncontrol, decreased physical activity, and pharmaceutical use, have been proposed to be involved in the development of DED (Phe and Roupret, 2012; Hatzimouratidis and Hatzichristou, 2014). A cross-sectional study has reported that the prevalence of DED is 4.6 and 45.5% for men aged

20–29 and 60–69 years, respectively (Fedele et al., 1998). Additionally, the prevalence of ED in men aged 21–30, 50–60, and >60 years has been reported to be 1.1, 55, and 75%, respectively, in another cohort of DM patients (Klein et al., 1996). Furthermore, the ED risk is higher in men with a long history of DM compared with men without DM (Bacon et al., 2002). A similar situation was observed in another crosssectional study, in which the prevalence was also significantly higher in patients with DM for >6 years than in those with DM for \leq 5 years (Fedele et al., 1998).

There is a link between glycemic control and DED. It has been reported that there is approximately 2–5-fold increased risk in ED patients without glycemic control compared with the patients whose glycemia is well controlled (Fedele et al., 2000). Although the mechanism whereby poor glycemic control induces ED in men with DM is still unclear, a recent study has reported that glycemic control can prevent ED *via* ameliorating endothelial damage and promoting vasculogenesis (Castela et al., 2017). Additionally, lack of physical activity has been shown to be associated with high prevalence of ED in men with DM (Zheng et al., 2006), and high physical activity reduces the risk of having ED (Cheng et al., 2007).

The hyperglycemia that accompanies DM is also an independent risk factor for ED among men with DM. Recent evidence has suggested that chronic hyperglycemia contributes to downregulating target-derived nerve growth factor (NGF), which is a trophic factor essential for the survival of small-diameter primary sensory neurons and autonomic nerves (Kim et al., 2009). NGF has been reported to significantly improve diabetes-induced ED through stimulation of testosterone biosynthesis. Finally, many drugs, including anti-hypertensives and psychiatric agents, which are commonly used in the treatment of DM, also contribute to the development of ED (Phe and Roupret, 2012).

Pathogenesis of DED

The development of DED is a complex and multifactorial process. The process appears to be affected by multiple physiological and psychological factors. The physiological factors include endothelial dysfunction, oxidative stress, and vascular and neurogenic causes. The psychological factors are depressive symptoms, anxiety, and decreased libido (Phe and Roupret, 2012). The multiple mechanisms involved in DED are illustrated in Figure 1.

Physiological factors

Endothelial dysfunction

Endothelial dysfunction is defined as the failure of the vascular endothelium to subserve its normal role in vasodilatation and/or vascular homeostasis which is considered as an important component of DED (Hatzimouratidis and Hatzichristou, 2014).





Multiple aspects of endothelial function are affected in DM, including impaired intercellular junctions of endothelial cells (ECs) (Rho et al., 2017), decreased nitric oxide (NO) bioavailability, and altered production of advanced glycation end-products in ECs (Phe and Roupret, 2012; Kamenov, 2015).

It is well known that the vascular endothelium is a selfbalancing tissue of the body and regulates vascular tension and structure. However, hyperglycemia can induce a significant increase in vascular permeability via downregulating vascular endothelial-cadherin, which is an important adherent junction protein that maintains cell polarity and integrity (Li et al., 2019). In turn, hyper-permeability of the vascular endothelium in the cavernous sinusoid and cavernous artery can promote the production of oxidized low-density lipoprotein (ox-LDL) to induce ED (Ryu et al., 2013).

Another important mechanism involved in DED is mediated through the endothelium by the action of NO. It is well known that the physiological erectile function requires various cell types. Firstly, nitric oxide (NO) is generated by corporal ECs, and the erectile response is triggered by the initial release of NO from the autonomic dilator nerve fibers. Then, NO stimulates the smooth muscle to produce cyclic guanosine monophosphate (cGMP), which dilates the vascular smooth muscle of the corpora cavernosa and thereby facilitates the blood supplying into cavernous sinus of penis, resulting in erection (Kavoussi et al., 2015). It has been reported that NO production is markedly decreased in the penis of diabetic rats Escrig et al., 2002). Additionally, supplement of L-arginine, a precursor of NO, could significantly improve erectile functions in DM patients [29]. It is well known that NO is produced by endothelial NO synthase (eNOS) and neuronal NO synthase (nNOS) in the corpora cavernosa (Burnett, 2006). Studies have shown that the eNOS level and nNOS-mediated cavernosal smoothmuscle relaxation in diabetic animals are reduced (Cartledge et al., 2001b; Toque et al., 2011). Although the mechanism underlying the downregulation of eNOS and nNOS in DM is not fully known, the hyperglycemia-induced overproduction of ROS may downregulate eNOS and nNOS (Koo and Vaziri, 2003). Additionally, endothelin (ET-1), which is upregulated in patients with DM, can suppress eNOS and downregulate NO via activating the RhoA/Rho-kinase pathway (Kalani, 2008; Kamenov, 2015).

Advanced glycation end products (AGEs) have been reported to accumulate in the corpus cavernosum of DM patients (Hatzimouratidis and Hatzichristou, 2014). The accumulation of AGEs can impair the endothelial and neuronal NO-mediated relaxation of the cavernosal smooth muscle (Cartledge et al., 2001b). Furthermore, AGEs can also form covalent bonds with vascular collagen, an interaction that increases vascular permeability and endothelial expression of adhesion molecules, thereby leading to vascular pathology (Wen et al., 2002). Accordingly, inhibitors of AGE formation can reverse the ED in diabetic rats (Usta et al., 2006).

Vasculopathy

Diabetic vasculopathy plays a role in the pathophysiology of ED. As discussed above, the process of erection needs the blood flow into the corpora cavernosae and cavernosal spaces. However, vascular structural changes have been described in men with DM (Hatzimouratidis and Hatzichristou, 2014). It has been reported that atherosclerosis and plaque formation, which are found in DM patients, can lead to ED due to penile macrovascular occlusion (Montorsi et al., 2005). Additionally, increased synthesis of the connective tissue of the smooth muscle in the corpus cavernosum

can also induce peripheral vascular disease, which leads to nerve ischemia and damage (Malavige and Levy, 2009). The mechanism of diabetic vasculopathy is associated with endothelial dysfunction, since AGE accumulation results in vascular thickening and atherosclerosis (Singh et al., 2001).

Neuropathy

Neuropathy often accompanies DM and is a significant factor to the pathophysiology of DED. It is known that the erectile process initially requires an autonomic neural input to direct the blood flow into the corpora cavernosae, and thus the autonomic nervous system is involved in this process (Dey and Shepherd, 2002). Then, the peripheral nervous system, including the pudendal nerve, is activated to induce the contraction of the bulbo-cavernous and ischiocavernosus muscles, whereby the venous outflow from the corpora cavernosa is inhibited (Defeudis et al., 2022). Therefore, the autonomic and peripheral nervous systems both participate in the erection process, and both autonomic and peripheral neuropathy occur in men with DM.

Autonomic neuropathy in DED is characterized by the reduced or absent parasympathetic activity needed. Parasympathetic activity is necessary to relax the smooth muscle of the corpus cavernosum, and the impaired parasympathetic activity in DED is associated with a decrease in NOS activity (Bleustein et al., 2002). Another study has found that patients with DM have reduced levels of norepinephrine and acetylcholinesterase in the corpus cavernosum tissue, and thus the autonomic-nerve-mediated relaxation of the penile smooth muscle is decreased (Saenz de Tejada et al., 1989). Furthermore, the peripheral neuropathy induced by DM can impair the sensory impulses from the shaft and the glans of the penis to the reflexogenic erectile center, and thus the contractile force of the bulbocavernosus and ischiocavernosus muscles is reduced (Herman et al., 2012). It has been reported that the dysfunction of the penile nerves in some men with DM was easier damaged when compared to the other peripheral nerves (Bleustein et al., 2002). According to previous studies, the pathophysiology of neuropathy involves several factors, including increased oxidative stress, accumulation of AGEs, and decreased NOS activity (Moore and Wang, 2006; Malavige and Levy, 2009).

Oxidative stress

Oxidative stress is easily triggered under hyperglycemia, which leads to the accumulation of reactive oxygen species (ROS) since the levels of antioxidants are reduced in DM patients (Cellek et al., 1999). In addition, mitochondrial respiratory chain leakage, NOS, and elevated xanthine oxidase activity all increase ROS levels (Cameron and Cotter, 2007). In turn, ROS can affect nitrergic neurons and endothelial cells and also change NOS expression and activity through multiple signaling pathways.

Increased production of ROS can accelerate the formation of AGEs and lipid peroxidation (Osawa and Kato, 2005). In turn, AGEs can upregulate adhesion molecules that mediate vascular damage and impair the relaxation of the smooth muscle in the corpus cavernosum of diabetic rats (Cartledge et al., 2001a). Additionally, AGEs have been shown to generate ROS and quench NO, thereby impairing the function of the endothelium (Soro-Paavonen and Forbes, 2006) and nitrergic relaxations (Cellek et al., 1999). Additionally, AGEs, in turn, induce ROS generation via disrupting mitochondrial electron transport chain and increasing NADPH oxidase activity (Lin et al., 2012). Furthermore, ROS can also interact with NO to form peroxynitrite and thereby reduce the available NO concentration. In addition, peroxynitrite has been reported to play a central role in atherogenesis via producing oxidized LDL (Pacher and Szabo, 2006). Third, the increase in ROS levels, particularly in the form of hydroxyl radicals or peroxynitrite, which cause cell damage and death, has been reported to increase the incidence of endothelial apoptosis, thereby leading to the denudation of the endothelium and further reduction in available NO (Hu et al., 2016). Fourth, Oxidative stress can stimulate the accumulation of glucose metabolites, which upregulate diacylglycerol (DAG), and DAG activates protein kinase C(PKC) (Cameron and Cotter, 2007). PKC activates several mechanisms that can modulate neurovascular activity via activating mitogen-activated kinases (MAPK) (Brownlee, 2005). MAPK inhibitors have been reported to improve somatic nerve function in diabetic rats (Price et al., 2004). Finally, it has been reported that superoxide anion, which is a type of ROS, has a direct vasoconstriction effect through mobilization of calcium ions (Katusic and Vanhoutte, 1989), whereby ED may be induced.

As discussed above, oxidative stress can lead to DED *via* multiple mechanisms. Therefore, elimination of oxidative stress is a promising therapeutic approach to treat DED. In fact, there are several anti-oxidant enzymes (especially vitamin E) that are extensively used in the treatment of DED. Vitamin E presumably attenuates diabetes-induced defective relaxations (Keegan et al., 1995). Other studies have suggested that vitamin E inhibits monocyte adhesion, cytokine release, and platelet adhesion via inhibiting PKC activation (Devaraj et al., 1996; Ganz and Seftel, 2000). However, the role of vitamin E needs to be further quantified in both animal and clinical studies before it can be used in humans.

Apoptosis

Apoptosis is also another factor underlying DED (Tarhan et al., 2009). It has been shown that the numbers of both endothelial and smooth-muscle cells are reduced and the ratio of TUNEL-positive cells in the corpus cavernosum is also increased in a mouse model of DED (Li et al., 2018). Consequently, eNOS is downregulated, and the smoothmuscle is damaged, whereby the relaxation function of the corpus cavernosum is impaired, and penile erection is diminished.

According to previous studies, multiple signaling pathways have been proposed to be involved in diabetes-induced apoptosis in the penile tissue (Zhang Z. et al., 2019). First, the mitogen-activated protein kinase (MAPK) signaling pathway is closely related to the occurrence and development of diabetes-induced ED. MAPK participates in various biological functions, including cell proliferation and apoptosis, and MAPK is activated under the condition of high glucose (Zhang Z. et al., 2019). The activation of MAPK can activate the downstream "peroxisome proliferatorsactivated receptor gamma" (PPAR γ) to induce the apoptosis of vascular smooth muscle cells (Wan et al., 2014), and inactivation of the MAPK/PPAR γ signaling alleviates diabetes-induced ED via suppression of the corpus cavernosal cell apoptosis (Zhang Z. et al., 2019).

Furthermore, oxidative stress induced by hyperglycemia triggers apoptosis. Nuclear factor E2-related factor 2 (Nrf2), which attenuates oxidative-stress-induced injury by upregulating several antioxidant genes, is downregulated in the corpus cavernosum of DED animal model, and enhanced expression of Nrf2 can ameliorate the erectile dysfunction (Wang et al., 2020). Additionally, ER stress activated by hyperglycemia can also increase the percentage of apoptotic cells in the corpus cavernosum of mice with DED, in association with decreased SOD activity (Zhang et al., 2018).

Psychological factors

Men with DM can have more psychosexual issues and easier to develop ED compared with men without DM, since DM is associated with depression. It demonstrated that the prevalence of depressive symptoms was high in DM patients (Anderson et al., 2001). Furthermore, DED is significantly associated with a disturbed mental state (Penson et al., 2003), and thus there is a possible reinforcing mechanism of the development of DED and depressive symptoms. Furthermore, the reduction in erectile function because of physical changes associated with DM can generate anxiety, worsening condition. A study demonstrated that DED is strongly associated with premature ejaculation and reduced libido, underlining the importance of possible psychological factors (Malavige et al., 2008). This hypothesis needs to be tested in men with DM, who have many factors that can potentially increase sexual inhibition and reduce excitation.

Short summary of the progress on deciphering DED pathophysiology

Considering the complex mechanism of DED, multiple signaling pathways and processes are involved in the pathogenesis of DED. One of the most important is that these processes do not function alone and are affected by each other.

According to a previous report, oxidative stress might be the first aspect triggered under hyperglycemia (Monnier et al., 2006). Subsequently, oxidative stress can affect endothelial function via reducing NO production and accelerating AGE accumulation. Additionally, AGEs can also stimulate the generation of ROS. Therefore, oxidative stress and AGEs reciprocally activate each other under hyperglycemia. In addition, AGEs can also lead to vasculopathy via inducing vascular thickening and atherosclerosis and result in neuropathy via impairing smooth-muscle relaxation. Further, chronic oxidative stress can also induce apoptosis and fibrosis via activating multiple signaling pathways. Finally, cavernous smooth muscle and endothelial cell apoptosis further reduce NO level. However, the link among these different aspects has not yet been fully investigated. Furthermore, psychological factors, such as less frequent erection, can also impair endothelial function.

Clinical evaluations of the effects of TCM on DED

TCM has been used for the effective treatment of DM and associated complications, with few side effects, for a long time in the Chinese history (Wang et al., 2018). There are at least three different types of TCM, including TCM formulae, crude extracts of herbs, and monomers of Chinese herbs. To date, the efficacies of several TCM formulae and crude extracts of herbs in treating DED have been assessed in randomized controlled trials.

Buyang Huanwu Decoction (BYHWD) is a classic traditional TCM formula and has 13 Chinese medicines components (Table 1). A randomized control trial showed that the International Index of Erectile Function-5 (IIEF-5) and World Health Organization Quality of Life Scale (WHOQOL-BREF) scores in the DED patients treated with BYHWD were both higher than those in the DED patients treated with vitamin B1 tablets (Yang et al., 2021). Furthermore, the concentration of testosterone was higher and the expression levels of estradiol (E2), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) were lower in the DED patients treated with BYHWD.

Huoxue Tongluo Qiwei Decoction (HXTLQWD) is composed of 12 types of Chinese medicines (Table 1). In a clinical trial, it showed that the IIEF-5 in the patients treated with HXTLQWD combined with tadalafil was significantly higher than that in the control group treated only with tadalafil, and total efficacy rate was higher in the treatment group than in the control group (81.8 vs. 51.5%) (Sun et al., 2021).

Yishen Huoxue Decoction (YSHXD) is composed of 16 Chinese medicines (Table 1) and is widely used to improve the semen quality of elderly men (Li et al., 2021). In a clinical trial, it showed that the IIEF-5 score and Erection Quality Scale (EQS) were higher in the group treated with YSHXD combined with a hypoglycemic drug than in the control group treated only with TABLE 1 Summary of the prescribed formulae and natural products from Traditional Chinese medicine used in clinical trials.

Name	Dosage Form	Species, concentration, source	Research design	Grouping and number of people		Treatment method		Treatment	Quality control reported	References
				Treatment group	Control group	Treatment group	Control group	Duration		
Buyang Huanwu Decoction (BYHWD)	Decoction	Astragalus mongholicus Bunge (30 g), Paeonia lactiflora Pall. (12 g), Angelica sinensis (Oliv.) Diels (12 g), Conioselinum anthriscoides 'Chuanxiong' (12 g), Carthamus tinctorius L. (12 g), Prunus davidiana (Carrière) Franch. (12 g), Phenetima aspergillum (12 g); Cornus officinalis Siebold & Zucc.(15 g); Dioscorea polystachya Turcz. (15 g); Bupleurum chinense DC. (12 g); Rehmannia glutinosa (Gaertn.) DC. (25 g); Pueraria montana (Lour.) Merr. (15 g); Panax notoginseng (Burkill) F.H.Chen (10 g). Prepared by Yang et al., 2021	Randomized controlled experiment	33	35	BYHWD (1 prescription/ day) + Vitamin B1 tablets (10 mg/day)	Vitamin B1 tablets (10 mg/day)	4 months	Prepared according to China Pharmacopoeia	Yang et al. (2021)
Huoxue Tongluo Qiwei Decoction (HXTLQWD)	Decoction	Paeonia lactiflora Pall. (30 g), Cyathula officinalis K.C.Kuan (15 g), Scolopendra subspinipes mutilans L. Koch (3 g), Hirudo nipponica Whitman. (6 g), Angelica sinensis (Oliv.) Diels (12 g), Gypsophila vaccaria (L.) Sm. (20 g), Epimedium brevicornu Maxim. (20 g), Gynochthodes officinalis (F.C.How) (20 g), Curcuma aromatica Salisb. (15 g), Citrus × aurantium L. (10 g), Bupleurum chimense DC. (12 g), Tribulus terrestris L (15 g). Purchased by Beijing Kangrentang Pharmaceutical Co., Ltd	Randomized controlled experiment	33	33	HXTLQWD(two bags/ day)+Tadalafil (5 mg/day)	Tadalafil (5 mg/day)	4 weeks	Prepared according to China Pharmacopoeia	Sun et al. (2021)
Yishen Huoxue Decoction (YSHXD)	Decoction	Lycium barbarum L. (15 g), Astragalus mongholicus Bunge (20 g), Rehmannia glutinosa (Gaertn.) DC. (15 g), Rubus idaeus L. (10 g), Cuscuta chinensis Lam. (10 g), Ligustrum lucidum W.T.Aiton (10 g), Allium tuberosum Rottler ex Spreng. (10 g), Morus alba L. (15 g), Rhodiola rosea L. (15 g), Angelica sinensis (Oliv.) Diels (15 g), Paeonia lactiflora Pall. (12 g), Dioscorea tokoro Makino ex Miyabe (20 g), Polygonatum sibiricum Redouté (20 g), Plantago asiatica L. (10 g), Ostrea gigas Thunberg (30 g), Achyranthes bidentata Blume (10 g). Prepared by Li et al., 2021	Randomized controlled experiment	30	30	YSHXD (1 prescription/day)	Levocarnitine oral Solution (10 ml/day)	3 months	Prepared according to China Pharmacopoeia	Li et al. (2021)
			Randomized controlled experiment	56	28	YSHXD (1 prescription/ day) + Hypoglycemia agent	Hypoglycemia agent		Prepared according to China Pharmacopoeia	Li et al. (2011)

TABLE 1 (Continued) Summary of the prescribed formulae and natural products from Traditional Chinese medicine used in clinical trials.

Name	Dosage Form	Species, concentration, source	Research design	Grouping and number of people		Treatment method		Treatment	Quality control reported	Reference
				Treatment group	Control group	Treatment group	Control group	Duration	-	
			Randomized controlled experiment	58	58	YSHXD (1 prescription/ day) + Thioctic acid injection (20 ml, 0.6 g/ daily)	Thioctic acid injection (20 ml, 0.6 g/day)	12 weeks	Prepared according to ChinaPharmacopoeia	Zhang and Qiu, (2017)
Yiqi Yangyin Huoxue Decoction (YQYYHXD)	Decoction	Astragalus mongholicus Bunge (30 g), Codonopsis pilosula (Franch.) Nannf. (30 g), Schisandra chinensis (Turcz.) Baill. (6 g), Ophiopogon japonicus (Thunb.) Ker Gawl. (10 g), Anemarrhena asphodeloides Bunge (10 g), Rehmannia glutinosa (Gaertn.) DC. (10 g), Reynoutria multiflora (Thunb.) Moldenke (10 g), Leonurus japonicus Houtt. (10 g), Angelica sinensis (Oliv.) Diels (10 g), Epimedium brevicornu Maxim. (10 g), Cinnamomum verum J.Presl (3 g), Scolopendra subspinipes mutilans (2 g), Ephedra sinica Stapf (3 g). Prepared by Cao et al., 2011	Randomized experiment	42		YQYYHXD(1 prescription/ day)+Hypoglycemia agent		3 months	Prepared according to ChinaPharmacopoeia	Cao et al. (2011)
Fufang Xuanju capsule	Capsule	Formica fusca Linnaeus, Epimedium brevicornu Maxim	Randomized controlled experiment	30	30	Fufang Xuanju capsule (3 times/day, 3 capsules for each time) + Hypoglycemia agent	Liuwei Dihuang Pill (3 times/day, 3 pills for each time + Hypoglycemia agent	3 months	Prepared according to ChinaPharmacopoeia	You et al. (2017)
		Cnidium monnieri (L.) Cusson, Lycium barbarum L								
		Purchased from Zhejiang Strong Pharmaceutical Co., Ltd. (0.4 g/one capsule)								
			Randomized controlled experiment	40	40	Fufang Xuanju capsule (3 times/day, 3 capsules for each time) +Tadalafil (10 mg)	Tadalafil (10 mg/day)	4 weeks	Prepared according to China Pharmacopoeia	Jiang et al. (2016)
Ziyin Zhuangyang capluse	Capsule	Rehmannia glutinosa (Gaertn.) DC.(20 g), Reynoutria multiflora (Thunb.) Moldenke (18 g), Lycium barbarum L. (18 g), Dioscorea oppositifolia L. (15 g), Broussonetia papyrifera (L.) L'Hér. Ex Vent. (15 g), Dendrobium nobile Lindl.(15 g), Ligustrum lucidum W.T.Aiton (15 g), Epimedium brevicornu Maxim. (10 g), Cuscuta chinensis Lam. (10 g), Cervus nippon	Randomized controlled experiment	30	30	Ziyin Zhuangyang capluse (1 prescription/day) +Hypoglycemia agent	Liuwei Dihuang Decoction+ Hypoglycemia agent	2 weeks	Prepared according to China Pharmacopoeia	Wu et al. (2015)

10.3389/fphar.2022.956173

TABLE 1 (Continued) Summary of the prescribed formulae and natural products from Traditional Chinese medicine used in clinical trials.

Name	Dosage Form	Species, concentration, source	Research design	Grouping and number of people		Treatment method		Treatment	Quality control reported	References
				Treatment group	Control group	Treatment group	Control group	Duration		
		Temminck (10 g), <i>Rosa laevigata</i> Michx. (10 g), <i>Albizia julibrissin</i> Durazz (8 g). Prepared by Yang and Dai, 2017								
Qianlieshutong capsules	Capsule	Phellodendron chinense C.K.Schneid., Paeonia lactiflora Pall., Angelica sinensis (Oliv.) Diels, Conioselinum anthriscoides 'Chuanxiong', Smilax glabra Roxb	Randomized controlled experiment	27	27	Qianlieshutong capsules (3 times/day, 3 capsules for each time) + insulin injection	Thioctic acid injection (20 ml, 0.6 g/ day) + insulin injection	3 weeks	Prepared according to China Pharmacopoeia	Guo, (2016)
		Sparganium stoloniferum (BuchHam. Ex Graebn.) BuchHam. Ex Juz., Alisma plantago- aquatica subsp. Orientale (Sam.) Sam., Portulaca oleracea L., Verbena officinalis L., Saxifraga stolonifera Curtis, Bupleurum falcatum L., Cyathula officinalis K.C.Kuan, Glycyrrhiza uralensis Fisch. Ex DC. Purchased from Baoding Tiaohao Pharmaceutical Co., Ltd. (0.4 g/one capsule)	Randomized controlled experiment	41	41	Qianlieshutong capsules (3 times/day, 3 capsules for each time) + insulin injection	Thioctic acid injection (20 ml, 0.6 g/ day) + insulin injection	3 weeks	Prepared according to China Pharmacopoeia	He and Hao, (2018)
Yougui pill	Pill	Rehmannia glutinosa (Gaertn.) DC., Cornus officinalis Siebold & Zucc., Dioscorea nipponica Makino, Lycium chinense Mill., Cervus nippon Temminck, Cuscuta chinensis Lam., Eucommia ulmoides Oliv., Angelica sinensis (Oliv.) Diels, Cinnamomum verum J.Presl, Aconitum carmichaeli Debeaux. Purchased from Jiangxi Yintao Pharmaceutical Co., Ltd. (0.45 g/one capsule)	Randomized controlled Experimen	14	14	Yougui pill (3 times/day, 4 capsules for each time) + Hypoglycemia agent	Tadalafil (10 mg/day) + Hypoglycemia agent	8 weeks	Prepared according to China Pharmacopoeia	Zhia et al. (2020)
			Randomized controlled experimen	43	43	Yougui pill (3 times/day, 4 capsules for each time) + Hypoglycemia agent	Testosterone undecanoate soft Capsules (3 times/day, 1 capsules for each time) + Hypoglycemia agent	8 weeks	Prepared according to China Pharmacopoeia	Wang, (2018)

the hypoglycemic drug (Li et al., 2011). Another randomized control trial showed that YSHXD can significantly improve the erectile function of DM patients via reducing the serum level of endothelin-1(ET-1) and increasing that of NO, which is associated with suppression of oxidative stress (Zhang and Qiu, 2017).

Yiqi Yangyin Huoxue Decoction (YQYYHXD) is composed of 13 Chinese medicines (Table 1). A clinical study showed that YQYYHXD improves erectile dysfunction in type II DM patients by increasing the serum level of testosterone and reducing the levels of luteinizing hormone (LH) and estradiol (E2) (Cao et al., 2011).

Fufang Xuanju capsule is another example of TCM remedy and is composed of 4 Chinese medicines (Table 1). A randomized clinical trial enrolled 80 patients, who were then divided into control and treatment groups. After 4 weeks of treatment, the IIEF-5 score of the patients in the group treated with Fufang Xuanju capsule combined with tadalafil was significantly higher than that in the control group treated only with tadalafil (Jiang et al., 2016). Furthermore, another clinical study showed that Xuanju capsule can improve erectile function of DM patients *via* reducing serum levels of AGEs and Ang II (You et al., 2017).

Ziyin Zhuangyang capsule is extracted from 12 Chinese medicines (Table 1). In a clinical study involving 60 DM patients, after 8 weeks of treatment with Ziyin Zhuangyang capsule, the IIEF-5 score of the patients substantially increased, and the erectile function was also improved, compared with the levels before the treatment (Wu et al., 2015). Another study demonstrated that Ziyin Zhuangyang capsule and sildenafil have obvious synergistic effects in alleviating DED and can improve the sexual self-confidence and life quality of patients (Yang and Dai, 2017). However, the underlying mechanisms were not investigated in these studies.

Qianlieshutong capsule is extracted from 12 Chinese herbs (Table 1). In a randomized control clinical trial, after 3 months of treatment with Qianlieshutong capsule combined with α -Lipoic acid, it could significantly improve erectile function in DM patients via upregulating NO, superoxide dismutase (SOD), and glutathione peroxidase (GSH) and downregulating homocysteine, MDA, and ET-1, compared with the patients treated only with α -Lipoic acid (Guo, 2016). Another clinical study involving 82 patients in a course of 3 weeks of treatment showed that Qianlieshutong capsule can significantly improve the IIEF-5 score and increase the serum levels of SOD, GSH, NOS, and NO in DED patients (He and Hao, 2018).

Yougui pill is a 10-component TCM remedy (Table 1) and is well known in TCM for its therapeutic effects on impotence. With the development of research, it also was used to effectively treat sexual dysfunction (Wang Y. et al., 2022). A randomized clinical trial involving 42 patients of DED found that 6 weeks of treatment with Yougui pill could significantly increase the IIEF-5 score of the patients compared with those of the placebo-treated group (Zhia et al., 2020). Although the IIEF-5 score of the patients treated with Yougui pill was lower than the patients orally treated with tadanafil, adverse reactions were lower in the Yougui pill group than in the tadanafil group. Additionally, Yougui pill enhances erectile function via upregulating testosterone (Wang, 2018).

Tribulus terrestris L. (TT) is a plant of the Zygophyllaceae family, and has been used for a long time in China. In a prospective, randomized, double-blind, placebo-controlled clinical trial, the IIEF-5 score was significantly better in the TT-treated ED patients than in the placebo-treated patients. Additionally, significant improvement in sexual function was observed in the TT-treated ED patients versus the placebo group (Kamenov et al., 2017). However, for DED patients, another prospective, randomized, double-blind trial showed that TT is not more effective than placebo in improving the symptoms of ED or total serum testosterone level (Santos et al., 2014). Therefore, further investigation is needed to elucidate the underlying mechanism of the protective effect of TT on DED.

The mechanisms whereby TCM ameliorates DED

Since TCM contain various chemical components and have numerous nutrition-related and pharmacological effects, the action mechanisms, pharmacokinetics, and therapeutic targets of most Chinese medicines are still elusive. There is currently no randomized controlled trial with a large sample size performed to evaluate the therapeutic effect of a TCM remedy on DED. However, numerous experimental studies, including animal studies and *in vitro* studies, have investigated the pharmacological mechanisms of various Chinese medicines in treating DED (Table 2). As discussed above, these biological pathways are interconnected, and these natural products may function in a multi-component and multi-target manner.

Rescued endothelial function

As discussed above, HXTLQWD can stimulate blood circulation and dredge collaterals, remove blood stasis, and calm wind. A recent study revealed that HXTLQWD can downregulate the protein and mRNA levels of PKC, rescue the function of endothelial cells and ultrastructure of the corpus cavernosum, and improve the erectile function of rats with DED (Li et al., 2022).

Tianjing Tongluo Decoction (TJTLD) is a Chinese herbal remedy composed of 4 Chinese medicines [*Epimedium brevicornu* Maxim.(15 g), *Rehmannia glutinosa* (Gaertn.) DC. (10 g), *Hirudo nipponica* Whitman (10 g). and *Cyathula officinalis* K.C.Kuan (10 g) Prepared according to China pharmacopoeia]. A previous study showed that TJTLD has

TABLE 2 The mechanisms by which Traditional Chinese medicine treat DED.

Property	Natural products	Type of study	Treatment method and sample size			Treatment	Targets or pathways	Chemical analysis	References
			Experiment group	Negative control group	Positive control group	Duration		-	
Rescued endothelial function	Huoxue Tongluo Qiwei Decoction (HXTLQWD)	Diabetes rat induced by STZ (55 mg/kg, i.p.)	HXTLQWD (7.8125 or 31.25 g/kg/day, suspension with deionized water) by gavage (n = 20)	The same volume of deionized water by gavage (n = 10)	LY333531 inhibitor (10 mg/kg) by gavage (n = 10)	8 weeks	Inhibit PKC signaling pathway	HPLC-MS	Li et al. (2022)
	Purchased from Beijing Kangrentang Pharmaceutical Co., Ltd								
	Tianjing Tongluo Decoction (TJTLD)	Diabetes rat induced by STZ (50 mg/kg, i.p.)	TJTLD (36 g/kg/day) by gavage (n = 10)	The same volume of saline by gavage $(n = 10)$	Tadalafil (0.2 mg/kg/time, two time/week) by gavage (n = 10)	4 weeks	Increase the release of sexual hormone levels		Shang et al. (2019a)
	Purchased from Beijing Tongrentang Pharmaceutical Co., Ltd	Diabetes rat induced by STZ (50 mg/kg, i.p.)	TJTLD (9.3 g/kg/day) by gavage $(n = 10)$	The same volume of saline by gavage $(n = 10)$	Tadalafil (0.2 mg/kg/time, two time/week) by gavage (n = 10)	4 weeks	Increase the activity of eNOS enzyme		Shang et al., 2019b
		Diabetes rat induced by STZ (50 mg/kg, i.p.)	TJTLD (9.3 g/kg/day) by gavage $(n = 10)$	The same volume of deionized water by gavage $(n = 10)$	Tadalafil (0.2 mg/kg/day) by gavage (n = 10)	4 weeks	Inhibit the RhoA/ Rho-kinase pathway		Yu et al. (2020)
	Gross saponins extracted form of Tribulus terrestris L.(GSTT)	Diabetes rat induced by STZ (50 mg/kg, i.p.)	GSTT (40 mg/kg/d) by gavage $(n = 6)$	The same volume of purified water	Sildenafil (5 mg/kg/day) by gavage $(n = 6)$	4 weeks	Increase eNOS activity		Zhang et al. (2019a)
	Purchased from Xi'an Wanfang Biotech Co.,			by gavage $(n = 6)$					
	Ltd.								
	Extract of Eucommia ulmoides Oliv. Leaf (EULE)	Diabetes rat induced by STZ (30 mg/kg, i.p.)	EULE (0.5%, 1%, 2% w/w mixed into high-fat diet) (n = 30)	The same volume of purified water	Sildenafil (3 mg/kg/day) by gavage (n = 10)	16 weeks	Increase the level of nitric oxide (NO) and activate Akt-eNOS pathway	UPLC	Fu et al. (2019)
	Prepared by Fu et al., 2019			by gavage $(n = 10)$					
	Yiyuanqiwei Pills	Diabetes rat induced by STZ (40 mg/kg, i.p.)	Yiyuanqiwei Pills (1.5, 3, 6 g/kg/day) by gavage (n = 30)	The same volume of saline by gavage $(n = 10)$	Sildenafil (5 mg/kg/day) by gavage ($n = 10$)	2 months	Increase nNOS activity, activate NO- cGMP signaling		Wang et al. (2022a)
	Prepared by Wang et al., 2022a								
	Wuzi Yanzong recipe	Diabetes rat induced by STZ (40 mg/kg, i.p.)	Wuzi Yanzong recipe (1.08 g/kg/day) by gavage (n = 10)	The same volume of purified water		30 days	Activate NO-cGMP signaling		Cao et al. (2018a)
	Prepared by Cao et al., 2018a			by gavage $(n = 10)$					
						8 weeks		HPLC	

TABLE 2 (Continued) The mechanisms by which Traditional Chinese medicine treat DED.

Property	Natural products	Type of study					Targets or pathways	Chemical analysis	References
		-	Experiment group	Negative control group	Positive control group	Duration		2	
Anti- atherosclerosis	Achyranthes bidentata Blume (ABR, 15 g) and Gypsophila vaccaria (L.)			The same volume of purified water			Reduce vascular endothelial growth factor A		Wang et al. (2021a)
	Sm. (SV, 10 g)			by gavage $(n = 6)$					
	Purchased by Beijing Kangrentang Pharmaceutical Co., Ltd	Diabetes rat induced by STZ (55 mg/kg, i.p.)	ABR-SV suspension (2.5 g/kg/day) by gavage						
Anti-oxidative properties	Panax notoginseng saponins (PNS) Purchased from Weikeqi Biological Technology	Diabetes rat induced by STZ (60 mg/kg, i.p.)	PNS (50, 100 and 150 mg/kg/ day) by i.p. (n = 18)	The same solutions of saline daily by i.p. $(n = 6)$		4 weeks	Increase SOD activity		Li et al. (2014)
	Danshen injection	Diabetes rat induced by STZ (60 mg/kg, i.p.)	Danshen injection (0.5 or 1 ml/kg/day) by i.p. (n = 20)	The same solutions of saline daily by i.p. (n = 10)		6 weeks	Increase SOD activity and reduce ROS	HPLC	Zhang et al. (2018)
	Purchased from Chiatai Qingchunbao Pharmaceutical Co., Ltd								
	Hirudo nipponica Whitman. (14 g) and Scolopendra subspinipes mutilans L. Koch (7 g)	Diabetes rat induced by STZ (55 mg/kg, i.p.)	The leech-centipede" suspension (0.15, 0.3, 0.6 g/kg/day) by gavage (n = 18)	The same volume of purified water	Tadalafil (0.5 mg/kg/day) by gavage (n = 6)	8 weeks	Increase SOD activity	UPLC-MS	Wang et al. (2021b)
	Purchased by Beijing Kangrentang Pharmaceutical Co., Ltd			by gavage $(n = 6)$					
	Yougui Capsule	Diabetes rat induced by STZ (60 mg/kg, i.p.)	Yougui Capsule (1.2, 2.4, 3.6 g/kg/day) by gavage (n = 39)	The same volume of purified water		12 weeks	Increase the activity of SOD and GSH		Liu et al. (2012)
	Purchased from Jiangxi Yintao Pharmaceutical Co., Ltd. (0.45 g/one capsule)			by gavage (n = 11)					
Anti-apoptosis	Bushen HuoXue Decoction (BSHXD)	Diabetes rat induced by STZ (55 mg/kg, i.p.)	BSHXD (3, 6 g/kg/day) by gavage (n = 13)	The same volume of saline by gavage (n = 8)		8 weeks	Activate protein kinase B		Yue et al. (2015)
	Prepared by Yue et al., 2015	Diabetes rat induced by STZ (40 mg/kg, i.p.)	Wuzi Yanzong recipe (1.08 g/kg/day) by gavage (n = 10)	The same volume of purified water		30 days	Reduce the expression of cleaved caspase-3		Cao et al. (2018a)
	Wuzi Yanzong recipe			by gavage $(n = 10)$					
	Prepared by Cao et al., 2018a								

TABLE 2 (Continued) The mechanisms by which Traditional Chinese medicine treat DED.

Property	Natural products	Type of study	Treatment method and sample size			Treatment	Targets or pathways	Chemical analysis	References
			Experiment group	Negative control group	Positive control group	Duration			
	Danshen injection	Diabetes rat induced by STZ (60 mg/kg, i.p.)	Danshen injection (0.5 or 1 ml/kg/day) by i.p. (n = 20)	The same solutions of saline daily by i.p. (n = 10)		6 weeks	Reduce the expression of cleaved caspase-3 and GADD153	HPLC	Zhang et al. (2018)
	Purchased from Chiatai Qingchunbao Pharmaceutical Co., Ltd								
	Ganoderma lucidum polysaccharide	Diabetes rat induced by STZ (60 mg/kg, i.p.)	Ganoderma lucidum polysaccharide (100, 400 mg/kg/day) by gavage (n = 6)	The same volume of purified water	Metformin (20 mg/kg/day) (n = 3)	8 weeks	Reduce the expression of cleaved caspase-3		Yao and Zhu, (2022)
	Purchased from Shanghai yuanye Bio- TechnologyCo., Ltd.			by gavage $(n = 3)$					
	Panax notoginseng saponins (PNS)	Diabetes rat induced by STZ (60 mg/kg, i.p.)	PNS (50, 100 and 150 mg/kg/ day) by i.p. (n = 18)	The same solutions of saline daily by i.p. $(n = 6)$		4 weeks	Increase the expression of Bcl-2		Li and Gou, (2013)
	Purchased from Weikeqi Biological Technology								

eNOS: endothelial nitric oxide synthase; GADD153: growth arrest and DNA, damage-inducible gene 153; high-performance liquid chromatography-mass spectrometry: HPLC-MS; NOS: neuronal nitric oxide synthase; PKC: protein kinase C; ROS: reactive oxygen species; SOD: superoxide dismutase; STZ: streptozocin; UPLC: ultra performance liquid chromatography; UPLC-MS: Ultra Performance Liquid Chromatography-mass spectrometry.

significantly beneficial effects on improving erectile function in diabetic rats and not only significantly promotes the sexual function via increasing the licking and sniffing times, the first back-climbing time, the straddling time, and insertion frequency but also upregulates serum testosterone level (Shang et al., 2019a). Although the underlying molecular mechanisms were not investigated in this study, two other studies showed that TJTLD could increase the activity of eNOS in penile spongiform and inhibit the RhoA/Rho-kinase pathway to rescue the endothelial function (Shang et al., 2019b; Yu et al., 2020).

Gross saponins extracted from *Tribulus terrestris* L. (GSTT) are the main active ingredients of *Tribulus terrestris* L. (TT), which is widely used to treat impotence. Previous studies have shown that TT has multiple biological effects, including improving glycolipid metabolism, attenuating oxidative stress, and inhibiting apoptosis (Zhang et al., 2010; Ercan and El, 2016). According to the study by Zhang et al., GSTT improves penile endothelial function via upregulating eNOS (Zhang H. et al., 2019).

Eucommia ulmoides Oliv. is used as a traditional medicine in China. The water extract of *Eucommia ulmoides* Oliv. leaf, generally known as Du-zhong tea, is a popular beverage in Asia and has also been used as a new edible remedy against hypertension (Zhu and Sun, 2018). A previous study showed that administration of *Eucommia ulmoides* Oliv. leaf extract significantly upregulates nitric oxide (NO) and cyclic guanosine monophosphate (cGMP) and activates the AkteNOS pathway to restore endothelial function of rat model of DED (Fu et al., 2019).

Yiyuanqiwei Pills is a classical herbal formula that stimulates blood circulation and nourishes blood. It is composed of approximately 20 Chinese medicines, namely Rehmannia glutinosa (Gaertn.) DC. (25 g), Cistanche deserticola Ma (20 g), Cervus nippon Temminck (20 g), Eucommia ulmoides Oliv. (15 g), Cuscuta chinensis Lam (15 g), Cullen corylifolium (L.). Medik. (15 g), Cynomorium coccineum subsp. songaricum (Rupr.) J.Léonard (15 g), Lycium barbarum L. (15 g), Epimedium brevicornu Maxim.(15 g), Panax ginseng C.A.Mey.(15 g), Achyranthes bidentata Blume.(15 g), Asparagus cochinchinensis (Lour.) Merr. (15 g), Hippocampus trimaculatus Leach. (1 pair), Bombyx mori Linnaeus. (10 g), Anax parthenope Selys. (9 g), Aspongopus chinensis Dallas. (9 g), Succinum (8 g), Syzygium aromaticum (L.) Merr. & L.M.Perry (8 g), Wurfbainia villosa var. villosa (8 g), and Dolomiaea costus (Falc.) Kasana & A.K.Pandey (9 g). According to Wang et al, Yiyuanqiwei pills can improve penile erection function in diabetic rats and reduce the pathological damage in the penile cavernous body (Wang D. et al., 2022). Especially, transmission electron microscopy observations have revealed that in diabetic rats, the blood sinus endothelium is broken, the blood sinus cavity is narrowed, and the endothelial cells are swollen, but these pathological features

are significantly ameliorated by Yiyuanqiwei Pills treatment, in association with upregulation of nNOS and eNOS and activation of the NO-cGMP signaling pathway (Wang D. et al., 2022).

Wuzi Yanzong recipe is a classical TCM prescription and is composed of 5 types of Chinese medicines [*Cuscuta chinensis* Lam. (40 g), *Lycium dasystemum* Pojark. (40 g), *Rubus idaeus* L. (20 g), *Plantago ovata* Forssk. (10 g) and *Schisandra chinensis* (Turcz.) Baill. (5 g). Prepared according to China pharmacopoeia]. It was reported that 4 months treatment of Wuzi Yanzong recipe could improve sperm quality via activating NO-cGMP pathway (Cao et al., 2018a).

Anti-atherosclerotic properties

Achyranthes bidentata Blume and Gypsophila vaccaria (L.) Sm. are two common Chinese herbs that are widely used in the clinical treatment of DM patients via strengthening the renal function and promoting blood circulation (Ma et al., 2017). It has been shown that vascular endothelial growth factor A (VEGFA) and angiotensin-converting enzyme (ACE) are upregulated in the corpus cavernosum of diabetic rats, and these proteins can promote the generation of mucosal blood vessels and increase the risk of vascular thrombosis (Scaldaferri et al., 2009). However, Achyranthes bidentata Blume and Gypsophila vaccaria (L.) Sm. can downregulate these two proteins (Wang et al., 2021a). Additionally, in comparison with healthy rats, the number of bloodcontaining sinuses in the cavernous body of diabetic rats is significantly reduced, accompanied by a reduction in the densities of endothelial and smooth-muscle cells. Combinatorial treatment with Achyranthes bidentata Blume and Gypsophila vaccaria (L.) Sm. increases the density of endothelial cells (Wang et al., 2021a).

Anti-oxidative properties

Panax notoginseng saponins (PNS), extracted from a Chinese herb named *Panax notoginseng* (Burkill) F.H.Chen, has an antioxidant activity. It has been reported that PNS improves erectile function in diabetic rats via increasing the activity of SOD and rescuing the functions of the endothelial and smooth-muscle cells in the penis (Li et al., 2014).

Danshen, a traditional Chinese herbal medicine, is the dried root of the plant *Salvia miltiorrhiza* Bunge. Accumulating studies have demonstrated that injection of Danshen has antioxidative effects in animal experiment (Raisi et al., 2021; Yuen et al., 2021). Further investigation has revealed that Danshen injection increases the activity of superoxide dismutase (SOD) and reduces the levels of reactive oxygen species (ROS) in the penile tissue of diabetic rats, thereby improving the erectile dysfunction (Zhang et al., 2018). Feng et al.

Hirudo nipponica Whitman. (leech) and *Scolopendra subspinipes mutilans* L. Koch (centipede) are used as two common TCM therapeutics. In a study, leech- or centipede-derived therapeutics could improve ED by inhibiting the expression of PKC upon 8 weeks of treatment, and this beneficial effect was found associated with attenuating oxidative-stress injury *via* increasing SOD activity (Wang et al., 2021b). Additionally, Yougui capsule has been shown to improve ED by enhancing the activity of SOD and GSH in the cavernous tissue of diabetic rats (Liu et al., 2012).

Anti-apoptotic properties

Bushen HuoXue Decoction (BSHXD) is a Chinese herbal compound composed of 5 Chinese medicines [*Cistanche deserticola* Ma (10 g), *Cervus nippon* Temminck (2 g), *Carthamus tinctorius* L. (9 g), *Panax ginseng* C.A.Mey. (9 g), and *Cyathula officinalis* K.C.Kuan (6 g), Prepared according to China pharmacopoeia]. In a previous study, administration of BSHXD to a rat model of DM for 4 weeks could inhibit the apoptosis of the cells in the corpus cavernosum smooth muscle via activating protein kinase B (AKT) (Yue et al., 2015).

It was reported that Wuzi Yanzong recipe could improve the sperm quality and rescue the testicular dysfunction in old rats via decreasing germ-cell apoptosis (Zhao et al., 2019). An animal study showed that Wuzi Yanzong recipe can substantially improve the reproductive and erectile function in DED, possibly by reducing the apoptosis of spermatogenic cells (Cao et al., 2018a). Another study revealed that Wuzi Yanzong recipe can reduce the blood sugar level and improve the pathological changes in the testicular tissue (Cao et al., 2018b). Furthermore, Wuzi Yanzong recipe exerts an anti-apoptotic effect via attenuating oxidative damage (Ma et al., 2018).

Furthermore, Danshen injection also reduces the number of apoptotic cells in the corpora cavernosum via suppressing caspase-3 activation and the expression of "growth arrest and DNA damageinducible gene 153" (GADD153) (Zhang et al., 2018).

Ganoderma lucidum polysaccharides are the main bioactive ingredients of *Ganoderma lucidum* (Curtis) P. Karst. It has been reported that Ganoderma lucidum polysaccharides can inhibit the apoptosis of sponge smooth muscle cells by suppressing caspase-3 activation and thereby improves erectile function in diabetic rats (Yao and Zhu, 2022). Furthermore, PNS protects endothelial and smooth-muscle cells from apoptosis via upregulating Bcl-2 and protects the function of penile cells, thereby improving erectile function in diabetic rats (Li and Gou, 2013).

Conclusions and perspectives

As mentioned above, the pathogenesis of DED is more complex than ED, and the development of DED involves

multiple risk factors. Therefore, multi-target treatments may be more effective in treating DED than targeting a single factor. However, recent clinical studies have indicated that chemical drugs do not have the ideal therapeutic effects. Therefore, the application of TCM to DED treatment is becoming a new trend. According to previous studies, Chinese herbs have multiple pharmacological activities and physiological effects, including anti-oxidative, anti-apoptotic, and antiatherosclerotic effects and rescue endothelial function. However, there are also several limitations in the published studies.

First, the sample size is too small in most of the clinical studies. There is a lack of large scale, multicenter, randomized, and controlled clinical trials on the use of these drugs to treat DED. Second, some of the findings still await verification through clinical studies, and although the clinical trials conducted to date have confirmed that the clinical symptoms are somewhat improved, the underlying mechanisms are still ambiguous. Third, there are also some toxic effects of Chinese herbs. According to the Chinese pharmacopoeia, some TCM are indeed toxic which could cause damage to the renal, nervous, respiratory, and reproductive system (Cai et al., 2019). However, published in vivo studies seldom mention the adverse effects of the treatments. In order to reduce the toxicity of TCM, the dosage of TCMs should not exceed the limit prescribed by the current China Pharmacopoeia. Fourth, the long effect of TCM on DED is not investigated in the current clinical studies, since TCM cannot be taken continuously. Fifth, TCM is often criticized and rejected by Western scientists, since the mechanisms of action, complex pharmacokinetics targets have not been fully classified and most of TCM formulae prescribed by doctors contain varied amounts of components for different person. Therefore, the clinical trials were mainly studied in China or east Asian countries. Finally, DED is caused by multiple factors; however, studies have mostly focused on examining the effects of TCM on one or a few aspects of DED.

In order to overcome these limitations, we believe that future research interests should be focused on at least two aspects. One is integrating TCM with network pharmacology analysis. It is well known that network pharmacology is a new subject which could analysis to search the key compounds and targets, and experimental verification to ensure the reliability of the predicted results (Luo et al., 2020). As discussed above, due to the complexity of TCM components and the interactions between TCM components and disease targets, it is difficult to fully classify the underlying molecular mechanism of TCM, that is also the major reason why western countries reject TCM. Indeed, some progress has been made in the TCM network pharmacology in recent years, including predicting herb targets, understanding biological foundation of diseases and syndromes, network regulation mechanisms of herbal formulae (Wang X. et al., 2021). However, there is few reports to investigate the role of TCM network pharmacology on DED. Second, there was no standardize the clinical research process to perform a large scale, multicenter and controlled trials. Therefore, it urgently needs to establish a unified standard for clinical research on DED.

Author contributions

BL conceptualized the research work. YaF and TS performed extensive literature search. YaF and wrote the manuscript draft. YuF drew the figure. BL critically reviewed the manuscript and supervised this project. All authors read and approved the final manuscript.

Funding

This work was supported by National Natural Science Foundation of China (Nos. 82074433 and No. 82174376).

References

Anderson, R. J., Freedland, K. E., Clouse, R. E., and Lustman, P. J. (2001). The prevalence of comorbid depression in adults with diabetes: A meta-analysis. *Diabetes Care* 24 (6), 1069–1078. doi:10.2337/diacare.24.6.1069

Bacon, C. G., Hu, F. B., Giovannucci, E., Glasser, D. B., Mittleman, M. A., and Rimm, E. B. (2002). Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. *Diabetes Care* 25 (8), 1458–1463. doi:10.2337/ diacare.25.8.1458

Bleustein, C. B., Arezzo, J. C., Eckholdt, H., and Melman, A. (2002). The neuropathy of erectile dysfunction. *Int. J. Impot. Res.* 14 (6), 433-439. doi:10. 1038/sj.ijir.3900907

Brownlee, M. (2005). The pathobiology of diabetic complications: A unifying mechanism. *Diabetes* 54 (6), 1615–1625. doi:10.2337/diabetes.54.6.1615

Bruzziches, R., Greco, E. A., Pili, M., Francomano, D., Spera, G., and Aversa, A. (2008). Redefining the role of long-acting phosphodiesterase inhibitor tadalafil in the treatment of diabetic erectile dysfunction. *Curr. Diabetes Rev.* 4 (1), 24–30. doi:10.2174/157339908783502389

Burnett, A. L. (2006). The role of nitric oxide in erectile dysfunction: Implications for medical therapy. J. Clin. Hypertens. 8 (12), 53-62. doi:10.1111/j.1524-6175.2006.06026.x

Cai, P., Qiu, H., Qi, F., and Zhang, X. (2019). The toxicity and safety of traditional Chinese medicines: Please treat with rationality. *Biosci. Trends* 13 (5), 367–373. doi:10.5582/bst.2019.01244

Cameron, N. E., and Cotter, M. A. (2007). Erectile dysfunction and diabetes mellitus: Mechanistic considerations from studies in experimental models. *Curr. Diabetes Rev.* 3 (3), 149–158. doi:10.2174/157339907781368977

Cao, S., Renzeng, C. D., Li, Y. P., Wu, P., Tong, L., and Bao, T. Y. (2018a). Effects of Wuzi Yanzong recipe and its disassembled formulae on apoptosis of spermatogenic cell and NO cGMP pathway in diabetic rats with erectile dysfunction. *Chin. High Alt. Med. Biol.* 39 (02), 112–117. doi:10.13452/j.cnki. jqmc.2018.02.009

Cao, S., Rezeng, C., Li, Y. P., Wu, P., Tong, L., and Bao, T. Y. (2018b). Effects of Wuzi Yanzong decoction and its disassembled formulae on reproductive function and sex hormone in diabetic rats with erectile dysfunction. *J. Liaoning Univ. Traditional Chin. Med.* 20 (07), 35–38. doi:10.13194/j.issn.1673-842x.2018.07.010

Cao, Y., Cao, A., Zhang, X., Zeng, H. y., Zhu, B., Xie, C. h., et al. (2011). [Efficacy and safety evaluation of two insulin treatment protocols using a continuous glucose monitoring system]. J. Zhejiang Chin. Med. Univ. 35 (02), 151–154.

Cartledge, J. J., Eardley, I., and Morrison, J. F. (2001a). Advanced glycation end-products are responsible for the impairment of corpus cavernosal smooth muscle relaxation seen in diabetes. *BJU Int.* 87 (4), 402–407. doi:10.1046/j.1464-410x.2001.00067.x

Cartledge, J. J., Eardley, I., and Morrison, J. F. (2001b). Nitric oxide-mediated corpus cavernosal smooth muscle relaxation is impaired in ageing and diabetes. *BJU Int.* 87 (4), 394–401. doi:10.1046/j.1464-410x.2001.00065.x

Castela, A., Gomes, P., Silvestre, R., Guardao, L., Leite, L., Chilro, R., et al. (2017). Vasculogenesis and diabetic erectile dysfunction: How relevant is glycemic control? *J. Cell. Biochem.* 118 (1), 82–91. doi:10.1002/jcb.25613

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Cellek, S., Rodrigo, J., Lobos, E., Fernandez, P., Serrano, J., and Moncada, S. (1999). Selective nitrergic neurodegeneration in diabetes mellitus - a nitric oxidedependent phenomenon. *Br. J. Pharmacol.* 128 (8), 1804–1812. doi:10.1038/sj.bjp. 0702981

Cheng, J. Y., Ng, E. M., Ko, J. S., and Chen, R. Y. (2007). Physical activity and erectile dysfunction: meta-analysis of population-based studies. *Int. J. Impot. Res.* 19 (3), 245–252. doi:10.1038/sj.ijir.3901521

Condorelli, R. A., Calogero, A. E., Favilla, V., Morgia, G., Johnson, E. O., Castiglione, R., et al. (2013). Arterial erectile dysfunction: Different severities of endothelial apoptosis between diabetic patients "responders" and "non responders" to sildenafil. *Eur. J. Intern. Med.* 24 (3), 234–240. doi:10.1016/j.ejim.2013.01.001

Defeudis, G., Mazzilli, R., Tenuta, M., Rossini, G., Zamponi, V., Olana, S., et al. (2022). Erectile dysfunction and diabetes: A melting pot of circumstances and treatments. *Diabetes. Metab. Res. Rev.* 38 (2), e3494. doi:10.1002/dmrr.3494

Devaraj, S., Li, D., and Jialal, I. (1996). The effects of alpha tocopherol supplementation on monocyte function. Decreased lipid oxidation, interleukin 1 beta secretion, and monocyte adhesion to endothelium. *J. Clin. Invest.* 98 (3), 756–763. doi:10.1172/JCI118848

Dey, J., and Shepherd, M. D. (2002). Evaluation and treatment of erectile dysfunction in men with diabetes mellitus. *Mayo Clin. Proc.* 77 (3), 276–282. doi:10.4065/77.3.276

El Taieb, M., Hegazy, E., and Ibrahim, A. (2019). Daily oral l-arginine plus tadalafil in diabetic patients with erectile dysfunction: A double-blinded, randomized, controlled clinical trial. *J. Sex. Med.* 16 (9), 1390–1397. doi:10.1016/j.jsxm.2019.06.009

Ercan, P., and El, S. N. (2016). Inhibitory effects of chickpea and Tribulus terrestris on lipase, alpha-amylase and alpha-glucosidase. *Food Chem.* 205, 163–169. doi:10.1016/j.foodchem.2016.03.012

Escrig, A., Marin, R., Abreu, P., Gonzalez-Mora, J. L., and Mas, M. (2002). Changes in mating behavior, erectile function, and nitric oxide levels in penile corpora cavernosa in streptozotocin-diabetic rats. *Biol. Reprod.* 66 (1), 185–189. doi:10.1095/biolreprod66.1.185

Fedele, D., Bortolotti, A., Coscelli, C., Santeusanio, F., Chatenoud, L., Colli, E., et al. (2000). Erectile dysfunction in type 1 and type 2 diabetics in Italy. *Int. J. Epidemiol.* 29 (3), 524–531. doi:10.1093/ije/29.3.524

Fedele, D., Coscelli, C., Santeusanio, F., Bortolotti, A., Chatenoud, L., Colli, E., et al. (1998). Erectile dysfunction in diabetic subjects in Italy. Gruppo italiano studio deficit erettile nei diabetici. *Diabetes Care* 21 (11), 1973–1977. doi:10.2337/diacare. 21.11.1973

Fink, H. A., Mac Donald, R., Rutks, I. R., Nelson, D. B., and Wilt, T. J. (2002). Sildenafil for male erectile dysfunction: A systematic review and meta-analysis. *Arch. Intern. Med.* 162 (12), 1349–1360. doi:10.1001/archinte.162.12.1349

Fu, H., Bai, X., Le, L., Tian, D., Gao, H., Qi, L. X., et al. (2019). Eucommia ulmoides Oliv. Leaf extract improves erectile dysfunction in streptozotocin-induced diabetic rats by protecting endothelial function and ameliorating hypothalamic-

pituitary-gonadal Axis function. Evid. Based. Complement. Altern. Med., 1782953. doi:10.1155/2019/1782953

Ganz, M. B., and Seftel, A. (2000). Glucose-induced changes in protein kinase C and nitric oxide are prevented by vitamin E. *Am. J. Physiol. Endocrinol. Metab.* 278 (1), E146–E152. doi:10.1152/ajpendo.2000.278.1.E146

Gawlik, K., Naskalski, J. W., Fedak, D., Pawlica-Gosiewska, D., Grudzien, U., Dumnicka, P., et al. (2016). Markers of antioxidant defense in patients with type 2 diabetes. *Oxid. Med. Cell. Longev.* 2016, 2352361. doi:10.1155/2016/2352361

Guo, J. (2016). The effect of Qianlieshutong capsule combined α - lipoic acid on serum homocysteine, nitric oxide and oxidative stress products in middle-aged and elderly patients with erectile dysfunction in type 2 diabetes mellitus. *Chin. J. Gerontology* 36 (18), 4476–4478.

Gur, S., Peak, T. C., Kadowitz, P. J., Sikka, S. C., and Hellstrom, W. J. (2014). Review of erectile dysfunction in diabetic animal models. *Curr. Diabetes Rev.* 10 (1), 61–73. doi:10.2174/1573399809666131126151024

Hatzimouratidis, K., and Hatzichristou, D. (2014). How to treat erectile dysfunction in men with diabetes: From pathophysiology to treatment. *Curr. Diab. Rep.* 14 (11), 545. doi:10.1007/s11892-014-0545-6

He, G. X., and Hao, C. J. (2018). Application effects of Qianlieshutong capsules and α -lipoic acid in type 2 diabetic middle-and-old-aged patients with erectile dysfunction. *Chin. J. Hum. Sex.* 27 (02), 28–31.

Herman, W. H., Pop-Busui, R., Braffett, B. H., Martin, C. L., Cleary, P. A., Albers, J. W., et al. (2012). Use of the Michigan neuropathy screening instrument as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: Results from the diabetes control and complications trial/epidemiology of diabetes interventions and complications. *Diabet. Med.* 29 (7), 937–944. doi:10.1111/j. 1464-5491.2012.03644.x

Hu, Y., Niu, X., Wang, G., Huang, J., Liu, M., and Peng, B. (2016). Chronic prostatitis/chronic pelvic pain syndrome impairs erectile function through increased endothelial dysfunction, oxidative stress, apoptosis, and corporal fibrosis in a rat model. *Andrology* 4 (6), 1209–1216. doi:10.1111/andr.12273

Jiang, C., Cao, Z. G., Chen, Q. C., Luo, Y., Wang, K., Xu, L., et al. (2016). The curative effect of compound Xuanju capsule combined with tadalafil in the treatment of diabetic erectile dysfunction. *J. Bengbu Med. Coll.* 41 (10), 1323–1325. doi:10.13898/j.cnki.issn.1000-2200.2016.10.020

Kalani, M. (2008). The importance of endothelin-1 for microvascular dysfunction in diabetes. *Vasc. Health Risk Manag.* 4 (5), 1061–1068. doi:10. 2147/vhrm.s3920

Kamenov, Z. A. (2015). A comprehensive review of erectile dysfunction in men with diabetes. *Exp. Clin. Endocrinol. Diabetes* 123 (3), 141–158. doi:10.1055/s-0034-1394383

Kamenov, Z., Fileva, S., Kalinov, K., and Jannini, E. A. (2017). Evaluation of the efficacy and safety of Tribulus terrestris in male sexual dysfunction-A prospective, randomized, double-blind, placebo-controlled clinical trial. *Maturitas* 99, 20–26. doi:10.1016/j.maturitas.2017.01.011

Katusic, Z. S., and Vanhoutte, P. M. (1989). Superoxide anion is an endotheliumderived contracting factor. *Am. J. Physiol.* 257 (2), H33–H37. doi:10.1152/ajpheart. 1989.257.1.H33

Kavoussi, P. K., Heberlein, K., Straub, A. C., Lowe, G. J., Oliver, J. L., Smith, R. P., et al. (2015). Recombinant PAI-1 therapy restores myoendothelial junctions and erectile function in PAI-1-deficient mice. *Andrologia* 47 (10), 1147–1152. doi:10. 1111/and.12395

Keegan, A., Walbank, H., Cotter, M. A., and Cameron, N. E. (1995). Chronic vitamin E treatment prevents defective endothelium-dependent relaxation in diabetic rat aorta. *Diabetologia* 38 (12), 1475–1478. doi:10.1007/BF00400609

Kim, H. C., Cho, Y. J., Ahn, C. W., Park, K. S., Kim, J. C., Nam, J. S., et al. (2009). Nerve growth factor and expression of its receptors in patients with diabetic neuropathy. *Diabet. Med.* 26 (12), 1228–1234. doi:10.1111/j.1464-5491.2009. 02856.x

Klein, R., Klein, B. E., Lee, K. E., Moss, S. E., and Cruickshanks, K. J. (1996). Prevalence of self-reported erectile dysfunction in people with long-term IDDM. *Diabetes Care* 19 (2), 135–141. doi:10.2337/diacare.19.2.135

Koo, J. R., and Vaziri, N. D. (2003). Effects of diabetes, insulin and antioxidants on NO synthase abundance and NO interaction with reactive oxygen species. *Kidney Int.* 63 (1), 195–201. doi:10.1046/j.1523-1755.2003.00728.x

Li, H., Chen, L. P., Wang, T., Wang, S. G., and Liu, J. H. (2018). Calpain inhibition improves erectile function in diabetic mice via upregulating endothelial nitric oxide synthase expression and reducing apoptosis. *Asian J. Androl.* 20 (4), 342–348. doi:10.4103/aja.aja_63_17

Li, H., and Gou, X. (2013). Antiapoptotic effects of Panax notoginseng saponins on erectile function in diabetic rats with erectile dysfunction. *J. Chongqing Med. Univ.* 38 (11), 1325–1330. Li, H., He, W. Y., Lin, F., and Gou, X. (2014). Panax notoginseng saponins improve erectile function through attenuation of oxidative stress, restoration of Akt activity and protection of endothelial and smooth muscle cells in diabetic rats with erectile dysfunction. *Urol. Int.* 93 (1), 92–99. doi:10.1159/000354878

Li, X., Feng, J. L., Chen, Z. L., Bao, B. H., Dai, H. H., Meng, F. C., et al. (2022). Mechanism by which Huoxue Tongluo Qiwei Decoction improves the erectile function of rats with diabetic erectile dysfunction. *J. Ethnopharmacol.* 283, 114674. doi:10.1016/j.jep.2021.114674

Li, X. X., Ling, S. K., Hu, M. Y., Ma, Y., Li, Y., and Huang, P. L. (2019). Protective effects of acarbose against vascular endothelial dysfunction through inhibiting Nox4/NLRP3 inflammasome pathway in diabetic rats. *Free Radic. Biol. Med.* 145, 175–186. doi:10.1016/j.freeradbiomed.2019.09.015

Li, Y., Pan, E., and Hu, X., Z. (2011). Clinical observation on the treatment of IIType diabetic erectile dysfunction by yishen Huoxue decoction combined with glucose-owering. *Liaoning J. Traditional Chin. Med.* 38 (11), 2227–2228.

Li, Z. M., Hu, S. L., Liu, T. J., and Sun, Z. (2021). Yishen Huoxue Decoction for infertility in elderly men with kidney deficiency and blood stasis. *Zhonghua Nan Ke Xue* 27 (6), 530–534.

Lin, N., Zhang, H., and Su, Q. (2012). Advanced glycation end-products induce injury to pancreatic beta cells through oxidative stress. *Diabetes Metab.* 38 (3), 250–257. doi:10.1016/j.diabet.2012.01.003

Liu, X. Q., Lv, Z., Sun, G., Guo, Z. H., and Guo, Z. J., (2012). Experiment on impact of Yougui capsule on eretile dysfunction in diabetic rats. *World Chin. Med.* 7 (05), 445–447.

Luo, E., Yang, Q., and Xu, W. (2019). The efficacy of low-dose tadalafil combined with Xuefu Zhuyu tablets in the treatment of diabetic erectile dysfunction. *China Prac. Med.* 14 (24), 111–112. doi:10.14163/j.cnki.11-5547/r.2019.24.062

Luo, T. T., Lu, Y., Yan, S. K., Xiao, X., Rong, X. L., and Guo, J. (2020). Network pharmacology in research of Chinese medicine formula: Methodology, application and prospective. *Chin. J. Integr. Med.* 26 (1), 72–80. doi:10.1007/s11655-019-3064-0

Ma, H. F., Liu, Y., Wang, B., Dang, J., Ma, J. X., Zhu, Y. T., et al. (2017). Clinical randomized controlled study of tongluo xifeng qiwei decoction in the treatment of erectile dysfunction. 26(02), 78–81.

Ma, N., Zhao, H. X., Chen, Q., You, X., Ma, Q. Y., Yang, S. Q., et al. (2018). Protective effect of Wuzi Yanzong recipe on testicular DNA oxidative damage in natural ageing rats. *Zhongguo Zhong Yao Za Zhi* 43 (14), 2985–2990. doi:10.19540/j. cnki.cjcmm.20180408.005

Maiorino, M. I., Bellastella, G., Della Volpe, E., Casciano, O., Scappaticcio, L., Cirillo, P., et al. (2017). Erectile dysfunction in young men with type 1 diabetes. *Int. J. Impot. Res.* 29 (1), 17–22. doi:10.1038/ijir.2016.38

Malavige, L. S., Jayaratne, S. D., Kathriarachchi, S. T., Sivayogan, S., Fernando, D. J., and Levy, J. C. (2008). Erectile dysfunction among men with diabetes is strongly associated with premature ejaculation and reduced libido. *J. Sex. Med.* 5 (9), 2125–2134. doi:10.1111/j.1743-6109.2008.00907.x

Malavige, L. S., and Levy, J. C. (2009). Erectile dysfunction in diabetes mellitus. J. Sex. Med. 6 (5), 1232–1247. doi:10.1111/j.1743-6109.2008.01168.x

Monnier, L., Mas, E., Ginet, C., Michel, F., Villon, L., Cristol, J. P., et al. (2006). Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. *JAMA* 295 (14), 1681–1687. doi:10.1001/jama.295.14.1681

Montorsi, P., Ravagnani, P. M., Galli, S., Rotatori, F., Briganti, A., Salonia, A., et al. (2005). The artery size hypothesis: A macrovascular link between erectile dysfunction and coronary artery disease. *Am. J. Cardiol.* 96 (12B), 19M–23M. doi:10.1016/j.amjcard.2005.07.006

Moore, C. R., and Wang, R. (2006). Pathophysiology and treatment of diabetic erectile dysfunction. *Asian J. Androl.* 8 (6), 675–684. doi:10.1111/j.1745-7262.2006. 00223.x

Musicki, B., and Burnett, A. L. (2007). Endothelial dysfunction in diabetic erectile dysfunction. *Int. J. Impot. Res.* 19 (2), 129–138. doi:10.1038/sj.ijir.3901494

Osawa, T., and Kato, Y. (2005). Protective role of antioxidative food factors in oxidative stress caused by hyperglycemia. *Ann. N. Y. Acad. Sci.* 1043, 440–451. doi:10.1196/annals.1333.050

Pacher, P., and Szabo, C. (2006). Role of peroxynitrite in the pathogenesis of cardiovascular complications of diabetes. *Curr. Opin. Pharmacol.* 6 (2), 136–141. doi:10.1016/j.coph.2006.01.001

Penson, D. F., Latini, D. M., Lubeck, D. P., Wallace, K. L., Henning, J. M., Lue, T. F., et al. (2003). Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the exploratory comprehensive evaluation of erectile dysfunction (ExCEED) database. *Diabetes Care* 26 (4), 1093–1099. doi:10.2337/diacare.26.4.1093 Phe, V., and Roupret, M. (2012). Erectile dysfunction and diabetes: A review of the current evidence-based medicine and a synthesis of the main available therapies. *Diabetes Metab.* 38 (1), 1–13. doi:10.1016/j.diabet.2011.09.003

Price, S. A., Agthong, S., Middlemas, A. B., and Tomlinson, D. R. (2004). Mitogen-activated protein kinase p38 mediates reduced nerve conduction velocity in experimental diabetic neuropathy: Interactions with aldose reductase. *Diabetes* 53 (7), 1851–1856. doi:10.2337/diabetes.53.7.1851

Raisi, A., Dezfoulian, O., Davoodi, F., Taheri, S., and Ghahremani, S. A. (2021). Salvia miltiorrhiza hydroalcoholic extract inhibits postoperative peritoneal adhesions in rats. *BMC Complement. Med. Ther.* 21 (1), 126. doi:10.1186/ s12906-021-03300-7

Rho, S. S., Ando, K., and Fukuhara, S. (2017). Dynamic regulation of vascular permeability by vascular endothelial cadherin-mediated endothelial cell-cell junctions. *J. Nippon. Med. Sch.* 84 (4), 148–159. doi:10.1272/jnms.84.148

Ryu, J. K., Jin, H. R., Yin, G. N., Kwon, M. H., Song, K. M., Choi, M. J., et al. (2013). Erectile dysfunction precedes other systemic vascular diseases due to incompetent cavernous endothelial cell-cell junctions. *J. Urol.* 190 (2), 779–789. doi:10.1016/j.juro.2013.02.100

Saenz de Tejada, I., Goldstein, I., Azadzoi, K., Krane, R. J., and Cohen, R. A. (1989). Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. *N. Engl. J. Med.* 320 (16), 1025–1030. doi:10.1056/NEJM198904203201601

Santos, C. A., Jr., Reis, L. O., Destro-Saade, R., Luiza-Reis, A., and Fregonesi, A. (2014). Tribulus terrestris versus placebo in the treatment of erectile dysfunction: A prospective, randomized, double blind study. *Actas Urol. Esp.* 38 (4), 244–248. doi:10.1016/j.acuro.2013.09.014

Scaldaferri, F., Vetrano, S., Sans, M., Arena, V., Straface, G., Stigliano, E., et al. (2009). VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. *Gastroenterology* 136 (2), 585–595. doi:10.1053/j.gastro. 2008.09.064

Shang, J. W., Mu, J., Sheng, W., Yu, X. D., and Liu, H. F. (2019a). Effect of tianjing tongluo formula and its herbal compositions on sexual hormone and function in the rats with diabetic erectile dysfunction. *World J. Integr. Traditional West. Med.* 14 (07), 937–940+977. doi:10.13935/j.cnki.sjzx.190713

Shang, J. W., Sheng, W., Li, X. R., Mu, J., He, X. D., and Liu, H. F. (2019b). Effects of tianjing tongluo decoction and its disassembled formulae on sex hormones and the expression of penile cavernosa eNOS enzyme in diabetic rats with erectile dysfunction. *Mod. Traditional Chin. Med. Materia Medica-World Sci. Technol.* 21 (03), 547–552.

Singh, R., Barden, A., Mori, T., and Beilin, L. (2001). Advanced glycation endproducts: A review. *Diabetologia* 44 (2), 129-146. doi:10.1007/s001250051591

Soro-Paavonen, A., and Forbes, J. M. (2006). Novel therapeutics for diabetic micro- and macrovascular complications. *Curr. Med. Chem.* 13 (15), 1777–1788. doi:10.2174/092986706777452515

Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., et al. (2022). IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Res. Clin. Pract.* 183, 109119. doi:10.1016/j.diabres.2021.109119

Sun, S., Wang, J. S., Xu, S. Q., Zhou, H., Li, H. S., Zhou, Y., et al. (2021). Clinical observation of Huoxue Tongluo Qiwei decoction combined with low dose tadalafil in the treatment of erectile dysfunction in diabetes with blood stasis and kidney deficiency. *Lishizhen Med. Materia Medica Res.* 32 (01), 124–126.

Tarhan, F., Demirel, G. Y., Kuyumcuoglu, U., Faydaci, G., and Eryildirim, B. (2009). Apoptosis of corpus cavernosum in patients with organic erectile dysfunction. *World J. Urol.* 27 (2), 235–240. doi:10.1007/s00345-008-0332-6

Toque, H. A., Tostes, R. C., Yao, L., Xu, Z., Webb, R. C., Caldwell, R. B., et al. (2011). Arginase II deletion increases corpora cavernosa relaxation in diabetic mice. *J. Sex. Med.* 8 (3), 722–733. doi:10.1111/j.1743-6109.2010.02098.x

Usta, M. F., Kendirci, M., Gur, S., Foxwell, N. A., Bivalacqua, T. J., Cellek, S., et al. (2006). The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin-induced diabetic rats: Preventive versus curative treatment. J. Sex. Med. 3 (2), 242–250. doi:10.1111/j.1743-6109.2006.00217.x

Vita, R., Benvenga, S., Giammusso, B., and La Vignera, S. (2019). Determinants of early response to low-intensity extracorporeal shockwaves for the treatment of vasculogenic erectile dysfunction: An open-label, prospective study. *J. Clin. Med.* 8 (7), E1017. doi:10.3390/jcm8071017

Wan, J., Xiao, Z., Chao, S., Xiong, S., Gan, X., Qiu, X., et al. (2014). Pioglitazone modulates the proliferation and apoptosis of vascular smooth muscle cells via peroxisome proliferators-activated receptor-gamma. *Diabetol. Metab. Syndr.* 6 (1), 101. doi:10.1186/1758-5996-6-101

Wang, D., Zhang, S. F., Jiang, X., Lyu, X., Zhu, T. P., and Lin, J. K. (2022a). Mechanism of Yiyuanqiwei pills in treating diabetic erectile dysfunction in rats. *Chin. J. Exp. Traditional Med. Formulae*, 1–14. Wang, H., Shi, S., and Wang, S. (2018). Can highly cited herbs in ancient Traditional Chinese medicine formulas and modern publications predict therapeutic targets for diabetes mellitus? *J. Ethnopharmacol.* 213, 101–110. doi:10.1016/j.jep.2017.10.032

Wang, H., Zhang, K., Ruan, Z., Sun, D., Zhang, H., Lin, G., et al. (2020). Probucol enhances the therapeutic efficiency of mesenchymal stem cells in the treatment of erectile dysfunction in diabetic rats by prolonging their survival time via Nrf2 pathway. *Stem Cell Res. Ther.* 11 (1), 302. doi:10.1186/s13287-020-01788-3

Wang, J. S., Feng, J. L., Dai, H. H., Chen, Z. L., Li, X., Bao, B. H., et al. (2021a). Potential mechanism of Achyranthis bidentatae radix plus semen vaccariae granules in the treatment of diabetes mellitus-induced erectile dysfunction in rats utilizing combined experimental model and network pharmacology. *Pharm. Biol.* 59 (1), 547–556. doi:10.1080/13880209.2021.1920621

Wang, J. S., Li, X., Chen, Z. L., Feng, J. L., Bao, B. H., Deng, S., et al. (2021b). Effect of leech-centipede medicine on improving erectile function in DIED rats via PKC signalling pathway-related molecules. *J. Ethnopharmacol.* 267, 113463. doi:10.1016/j.jep.2020.113463

Wang, J. Y. (2018). Effect of Yougui capsule combined with testosterone undecanoate on diabetes induced erectile dysfunction. *Chin. J. Rural Med. Pharm.* 25 (10), 49–50. doi:10.19542/j.cnki.1006-5180.001614

Wang, L., Peng, W., Zhao, Z., Zhang, M., Shi, Z., Song, Z., et al. (2021c). Prevalence and treatment of diabetes in China, 2013-2018. *JAMA* 326 (24), 2498–2506. doi:10.1001/jama.2021.22208

Wang, X., Wang, Z. Y., Zheng, J. H., and Li, S. (2021d). TCM network pharmacology: A new trend towards combining computational, experimental and clinical approaches. *Chin. J. Nat. Med.* 19 (1), 1–11. doi:10.1016/S1875-5364(21)60001-8

Wang, Y., Shi, C., Yu, W., Jiao, W., and Shi, G. (2022b). Efficacy of Yougui pill combined with Buzhong Yiqi decoction in alleviating the sexual dysfunction in female rats through modulation of the gut microbiota. *Pharm. Biol.* 60 (1), 46–55. doi:10.1080/13880209.2021.2010774

Wen, Y., Skidmore, J. C., Porter-Turner, M. M., Rea, C. A., Khokher, M. A., and Singh, B. M. (2002). Relationship of glycation, antioxidant status and oxidative stress to vascular endothelial damage in diabetes. *Diabetes Obes. Metab.* 4 (5), 305–308. doi:10.1046/j.1463-1326.2002.00212.x

Wu, Q., You, C., and Dai, N. (2015). Clinical curative effect observation of Ziyin Zhuangyang capluse in treating type 2 Diabetic Erectile Dysfunction. *Clin. J. traditional Chin. Med.* 27 (11), 1601–1604.

Yang, H., and Dai, N. (2017). Clinical observation of shisanwei Ziyin Zhuangyang capsule combined sildenafi l in treating diabetic erectile dysfunction (yin and yang defi ciency syndrome). *Clin. J. traditional Chin. Med.* 29 (02), 248–250. doi:10. 16448/j.cjtcm.2017.0080

Yang, H., Yao, L., and Xu, Z. (2021). The efficacy of Buyang Huanwu Decoction on diabetic erectile dysfunction. *CHINA Mod. Dr.* 59 (12), 130–133.

Yao, X. L., and Zhu, H. J. (2022). Effects of Ganoderma lucidum polysaccharide on oxidative stress, pathological changes and mitochondrial dysfunction in rats with erectile dysfunction of diabetes mellitus. *Chin. J. Traditional Med. Sci. Technol.* 29 (03), 373–378.

Yin, Y., D., and Fang, C. H. (2019). Research progress of traditional Chinese medicine on diabetic erectile dysfunction. *Clin. J. traditional Chin. Med.* 31 (11), 2027–2030. doi:10.16448/j.cjtcm.2019.0589

You, C. J., Wu, Q., Wang, X. Y., and Yang, X. Y. (2017). Clinical curative effect of Fufang Xuanju capsule in the treatment of diabetic erectile dysfunction and impact on AGEs and AngII. *Chin. J. Hum. Sex.* 26 (03), 93–96.

Yu, X., D., Liu, R. J., Wang, J. S., Deng, S., Bao, B. H., and Shang, J. W. (2020). Replenishing essence and dredging collaterals formula ameliorates erectile function through down-regulating the RhoA/rho pathway in DIED rats. *Mod. Traditional Chin. Med. Materia Medica-World Sci. Technol.* 22 (06), 2087–2094.

Yue, Z., Ma, W. J., Qin, M., Liu, B.-X., Ke, M. H., and Wang, C. H. (2015). Mechanism of invigorating kidney and activating blood recipe for the treatment of diabetic erectile dysfunction in rats. *J. Beijing Univ. Traditional Chin. Med.* 38 (07), 462–466+461.

Yuen, C. W., Murugaiyah, V., Najimudin, N., and Azzam, G. (2021). Danshen (Salvia miltiorrhiza) water extract shows potential neuroprotective effects in *Caenorhabditis elegans. J. Ethnopharmacol.* 266, 113418. doi:10.1016/j.jep.2020. 113418

Zhang, H., Tong, W. T., Zhang, C. R., Li, J. L., Meng, H., Yang, H. G., et al. (2019a). Gross saponin of Tribulus terrestris improves erectile dysfunction in type 2 diabetic rats by repairing the endothelial function of the penile corpus cavernosum. *Diabetes Metab. Syndr. Obes.* 12, 1705–1716. doi:10.2147/DMSO. S205722

Zhang, L., and Qiu, R. (2017). Effect of yishen Huoxue decoction combined with thioctic acid on serum of hcy NOET-1 and oxidative stress in patients with type

2 diabetes mellitus with erectile dysfunction. J. Liaoning Univ. Traditional Chin. Med. 19 (12), 199-202.

Zhang, S., Li, H., and Yang, S. J. (2010). Tribulosin protects rat hearts from ischemia/reperfusion injury. *Acta Pharmacol. Sin.* 31 (6), 671–678. doi:10.1038/aps. 2010.45

Zhang, Y., Chen, J., Ji, H., Xiao, Z. G., Shen, P., and Xu, L. H. (2018). Protective effects of Danshen injection against erectile dysfunction via suppression of endoplasmic reticulum stress activation in a streptozotocin-induced diabetic rat model. *BMC Complement. Altern. Med.* 18 (1), 343. doi:10.1186/s12906-018-2414-3

Zhang, Z., Zhang, H. Y., Zhang, Y., and Li, H. (2019b). Inactivation of the Ras/ MAPK/PPARγ signaling axis alleviates diabetic mellitus-induced erectile dysfunction through suppression of corpus cavernosal endothelial cell apoptosis by inhibiting HMGCS2 expression. *Endocrine* 63 (3), 615–631. doi:10.1007/s12020-018-1810-2 Zhao, H., Ma, N., Liu, Z., Wang, T., Yuan, C., He, Y., et al. (2019). Protective effect of Wuzi Yanzong recipe on testicular dysfunction through inhibition of germ cell apoptosis in ageing rats via endoplasmic reticulum stress. *Andrologia* 51 (2), e13181. doi:10.1111/and.13181

Zheng, H., Fan, W., Li, G., and Tam, T. (2006). Predictors for erectile dysfunction among diabetics. *Diabetes Res. Clin. Pract.* 71 (3), 313–319. doi:10.1016/j.diabres. 2005.07.011

Zhia, X. Y., Ge, M. Y., and Zhao, J. H. (2020). Clinical study of Yougui Pill in the treatment of diabetic erectile dysfunction with syndrome of deficiency of kidney yin and yang. *Shanghai J. Traditional Chin. Med.* 54 (1), 61–63. doi:10.16305/j.1007-1334.2020.S1.020

Zhu, M. Q., and Sun, R. C. (2018). Eucommia ulmoides oliver: A potential feedstock for bioactive products. J. Agric. Food Chem. 66 (22), 5433–5438. doi:10. 1021/acs.jafc.8b01312